Bessemer Group
CRNX

Bessemer Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bessemer Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26K Sell
683
-2,556
-79% -$95K ﹤0.01% 1904
2026
Q1 		$117K Buy
3,239
+128
+4% +$5.72K ﹤0.01% 1490
2025
Q4 		$145K Buy
3,111
+11
+0.4% +$490 ﹤0.01% 1423
2025
Q3 		$129K Buy
3,100
+2,855
+1,165% +$91.3K ﹤0.01% 1226
2025
Q2 		$7K Buy
+245
New +$7.57K ﹤0.01% 1917
2025
Q1 		– Sell
-70
Closed -$4K – 2488
2024
Q4 		$4K Sell
70
-165
-70% -$9.23K ﹤0.01% 2047
2024
Q3 		$12K Buy
235
+43
+22% +$2.22K ﹤0.01% 1617
2024
Q2 		$9K Buy
+192
New +$8.87K ﹤0.01% 1543

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bessemer Group's CRNX Position: Q2 2026 in Review

Bessemer Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 79% in Q2 2026, selling an estimated $95K and leaving 683 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #1904.

Bessemer Group first reported a position in CRNX in Q2 2024 and has held it in 8 quarters since. The position peaked at $145K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Bessemer Group held 683 shares of Crinetics Pharmaceuticals worth $26K as of Q2 2026.
  • Bessemer Group sold 2,556 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $95K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1904 holding.
  • Bessemer Group first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Bessemer Group's Crinetics Pharmaceuticals position peaked at $145K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.